Oncology Institute(NASDAQ) TOI

Market CapN/A

Since IPO (2020)-33%

5 Year-35%

1 Year+75%

1 Month+22%

Premium Feature

Moneyball Superscore

66/100

N/A

Oncology Institute last closing stock price
Metric	Price	Date
Last close	USD 6.47	2026-08-21

Oncology Institute stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0.23%	USD 6.45	2026-08-14
1 month	+22.21%	USD 5.29	2026-07-22
3 month	+40.85%	USD 4.59	2026-05-22
Year to date	+81.6%	USD 3.56	2025-12-31
1 year	+75.2%	USD 3.69	2025-08-21
3 year	+689.38%	USD 0.82	2023-08-22
5 year	-34.7%	USD 9.90	2021-08-20
Since inception	-33.35%	USD 9.70	2020-06-04

Oncology Institute Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$587.24M

Net Income (TTM)

-$36.29M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 6, 2026

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 6, 2026

TOI News

Getty - surprised interested amazed wow glasses

A Mysterious Stock Has Rallied Over 950% This Year. Here's 1 Key Reason Why Investors Are Turning Bullish

Selena MaranjianNov 21, 2025

TOI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oncology Institute

The Oncology Institute helps adults and seniors manage cancer care. It provides doctor visits, cancer drugs, and support programs. Patients get treatment, medication, and help navigating complex health systems.

What’s in the TOI Toolbox?

Physician Services (47%): Cancer doctor visits, chemotherapy, and radiation for adult and senior patients.
Dispensary (52%): In-house pharmacy for oral and injectable cancer drugs, both in clinics and by mail.
Clinical Trials & Other (1%): Access to research studies, palliative care, and outpatient stem cell transplants.
Infusion Services: On-site delivery of cancer drugs through intravenous (IV) infusions.
Patient Support: Help with care coordination, insurance, and navigating treatment options.

Growth Moves: The TOI Expansion Playbook

Expanded to 66 clinics across five U.S. states by 2025.
Entered a profit-sharing partnership with Helios CR, Inc. for clinical trials in 2025.
Launched cost reduction initiatives in 2025, and announced plans to pilot AI for insurance approvals.
Raised $16.5 million in a private placement in March 2025.
Established an at-the-market equity offering facility for up to $15 million in 2025.

Why TOI Isn’t Just Another Clinic

TOI integrates direct cancer care with cost management for patients and insurers. Its in-house pharmacy and coordinated care model streamline treatment and reduce administrative hurdles. The company’s focus on value-based contracts and automation supports operational efficiency.

Five Things You Need to Know

Revenue was $120 million in Q2 2025, up 21.5% year-on-year.
Dispensary segment led with 52% of Q2 2025 revenue, up 40.8% year-on-year.
Operating loss improved to $11 million in Q2 2025, from $16 million in Q2 2024.
Net cash used in operations was $15 million for the first half of 2025, down from $32 million.
TOI had $30 million in cash and $86 million in debt as of June 2025.

Bottom Line

TOI has grown by expanding clinics, pharmacy services, and research partnerships. The company continues to adapt its model to balance growth and cost control.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

641

CEO

Daniel Virnich, MD, MBA

Website

www.theoncologyinstitute.com

Headquarters

Cerritos, CA 90703, US

TOI Financials

Key Financial Metrics (TTM)

Gross Margin

15.69%

Operating Margin

-4.44%

Net Income Margin

-6.18%

Return on Equity

209.81%

Return on Capital

-41.02%

Return on Assets

-20.36%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$63.38M

Operating Income

-$26.09M

EBITDA

-$18.54M

Operating Cash Flow

$328.00K

Capital Expenditure

-$3.61M

Free Cash Flow

-$3.29M

Cash & ST Invst.

$41.09M

Total Debt

$24.61M

Oncology Institute Performance Analysis

Oncology Institute annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 252,483,000	24.4%
2023	2023-12-31	USD 324,239,000	28.4%
2024	2024-12-31	USD 393,412,000	21.3%
2025	2025-12-31	USD 502,729,000	27.8%

Oncology Institute sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	14.0%
Q4	2025-12-31	3.9%
Q1	2026-03-31	3.9%
Q2	2026-06-30	9.4%

Oncology Institute annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.21	27.7%
2023	2023-12-31	USD -0.92	336.8%
2024	2024-12-31	USD -0.71	-23.3%
2025	2025-12-31	USD -0.54	-22.9%

Oncology Institute sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	6.7%
Q4	2025-12-31	71.4%
Q1	2026-03-31	50.0%
Q2	2026-06-30	-300.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$161.28M

+34.6%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

641

N/A

Net Income

-$9.79M

+42.4%

EBITDA

-$2.78M

+79.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$41.09M

+35.7%

Total Debt

$24.61M

-76.2%

Accounts Receivable

$66.71M

+19.9%

Inventory

$20.01M

+26.8%

Long Term Debt

$17.38M

-81.9%

Short Term Debt

$7.23M

-1.1%

Return on Assets

-20.36%

N/A

Return on Invested Capital

-31.32%

N/A

Free Cash Flow

$11.03M

+196.7%

Operating Cash Flow

$11.94M

+217.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ACHCAcadia Healthcare Company, Inc.

ACHCAcadia Healthcare Company, Inc.$27.82+3.15%

PAIYYAesthetic Medical International Holdings Group Limited

PAIYYAesthetic Medical International Holdings Group Limited$0.02+0.00%

PIIIP3 Health Partners Inc.

PIIIP3 Health Partners Inc.$10.31-0.24%

SNDASonida Senior Living, Inc.

SNDASonida Senior Living, Inc.$39.56+0.74%

TNGXTango Therapeutics, Inc.

TNGXTango Therapeutics, Inc.$23.88+1.57%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.77+0.10%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$43.68+0.06%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.41+0.06%

MARAMara Holdings

MARAMara Holdings$11.26+0.01%

NVDANvidia

NVDANvidia$214.72-0.01%

INTCIntel

INTCIntel$90.07-0.02%

MRNAModerna

MRNAModerna$145.13+0.09%

Questions About TOI

What is the current price of Oncology Institute?

Oncology Institute is trading at N/A per share.

What is the 52-week range for Oncology Institute?

Over the past 52 weeks, Oncology Institute has traded between N/A and N/A.

How much debt does Oncology Institute have?

As of the most recent reporting period, Oncology Institute reported total debt of $104.48M.

How much cash does Oncology Institute have on hand?

Oncology Institute reported $41.09M in cash and cash equivalents in its most recent financial results.

What is Oncology Institute’s dividend yield?

Oncology Institute does not currently have a dividend yield.

Oncology Institute(NASDAQ) TOI

Oncology Institute Financials at a Glance

TOI News

A Mysterious Stock Has Rallied Over 950% This Year. Here's 1 Key Reason Why Investors Are Turning Bullish

This Healthcare Stock Is Up 1,000%, Outpacing Nvidia, Tesla, and Apple Combined

Oncology Institute Sales Jump 22 Percent

The Oncology Institute Q2 Revenue Surges

Oncology Institute Delivers a Mixed Q3

TOI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Oncology Institute

What’s in the TOI Toolbox?

Growth Moves: The TOI Expansion Playbook

Why TOI Isn’t Just Another Clinic

Five Things You Need to Know

Bottom Line

TOI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Oncology Institute Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TOI

What is the current price of Oncology Institute?

What is the 52-week range for Oncology Institute?

How much debt does Oncology Institute have?

How much cash does Oncology Institute have on hand?

What is Oncology Institute’s dividend yield?

Premium Investing Services